Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer

J-Ph, Peyrat; Fournier, Joëlle; Bonneterre, Jacques; Vanlemmens, Laurence; Lubin, R.; Soussi, Thierry

doi:10.1016/s0140-6736(95)90523-5

Cited by 121 publications

(55 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The impact on survival by anti-p53 antibodies was not dependent on covariation with stage, which was also indicated by the lack of correlation between level of anti-p53 antibodies and clinical stage. This observation has also been made by other investigators (Schlichtholz et al, 1992;Peyrat et al, 1995), who found no significant correlation between p53 antibodies and clinical stage.…”

Section: Discussionsupporting

confidence: 87%

“…In addition, the present study and others (Schlichtholz et al, 1992;Mudenda et al, 1994;Peyrat et al, 1995) demonstrate that presence of p53 autoantibodies is indicative of a worsened prognosis. Perhaps p53 mutation could be viewed as an event that speeds up the disease development, and thus be regarded as a marker for a more aggressive behaviour of the tumour (Davidoff et al, 1991).…”

Section: Discussionsupporting

confidence: 78%

“…Increased p53 protein amounts in tumour cells are indicative of mutated p53 (Davidoff et al, 1991b). An increase of p53 protein in tumours may elicit an immunological response (Winter et al, 1992), and therefore the finding of an association between serological anti-p53 response and survival in breast cancer is not surprising and has also been made by others (Peyrat et al, 1995). The multivariate analysis indicated that anti-p53 antibody level is an independent prognostic variable.…”

Section: Discussionmentioning

confidence: 81%

“…There are also observations indicating that only tumours with missense mutations of p53, resulting in p53 overexpression, elicit p53 antibodies (Davidoff et al, 1992;Winter et al, 1992;Lubin et al, 1993;Houbiers et al, 1995). Anti-p53 antibodies have also been reported to indicate a poor prognosis in patients with breast cancer (Schlichtholz et al, 1992;Peyrat et al, 1995).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study

et al. 1999

View full text Add to dashboard Cite

To perform an epidemiological evaluation of the predictive value of p53 autoantibodies in breast cancer, we measured antibodies against p53 in serum samples from 165 breast cancer patients in comparison with serum samples from 330 healthy controls, selected from the same population as the cases and matched for age, sex and specimen storage time. Median age of patients was 51 years (range 25–64 years). Presence of serum p53 autoantibodies was analysed by enzyme-linked immunosorbent assay (ELISA) and confirmed by Western blotting. The lower ELISA reactivities were similar for cases and controls, but presence of high-level reactivity was more common among cases than among controls [odds ratio (OR) 9.03, 95% confidence interval (CI) 2.40–50.43]. Presence of Western blot-detected p53 autoantibodies had a very similar association (OR 10.8, CI 3.0–59.4). Among the cases, we also studied whether there was any correlation between level of anti-p53 antibodies and stage of the disease or survival. There was no significant correlation between presence of antibodies and stage of the disease. There was a significant negative correlation between presence of p53 antibodies and survival ( P = 0.003). A stepwise multivariate Cox regression analysis showed that T-stage, age and presence of anti-p53 antibodies were significant independent prognostic variables, with a dose-dependent negative effect on survival for all three variables. We conclude that presence of anti-p53 antibodies are of significance both for the risk of having breast cancer and the risk of dying from breast cancer. 1999 Cancer Research Campaign

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionsupporting

confidence: 78%

Section: Discussionmentioning

confidence: 81%

mentioning

confidence: 99%

See 2 more Smart Citations

Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study

et al. 1999

View full text Add to dashboard Cite

show abstract

“…the presence of anti-p53 in serum is significantly correlated with high-grade histologv. historv of second primary cancer and poor prognosis : Peyrat et al 1995. In addition.…”

mentioning

confidence: 99%

Measurement and evaluation of serum anti-p53 antibody levels in patients with lung cancer at its initial presentation: a prospective study

Segawa

Kageyama²,

Suzuki³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

Summary Anti-p53 antibodies in sera are known to be products of the host immune response to mutated p53 protein, and are present in some patients with various types of cancer. In this study, we measured serum anti-p53 antibody levels in 52 patients with lung cancer and 63 normal volunteers to determine the relationship between anti-p53 antibody level and clinical features of lung cancer patients. Anti-p53 antibody level was measured by an enzyme-linked immunosorbent assay and expressed as an anti-p53 antibody index, defined as the ratio of absorption of serum sample to that of p53-positive serum. The median anti-p53 antibody index was 6.6 for lung cancer patients, and higher than that in normal volunteers (1.7) (P = 0.0000). For lung cancer patients, significant differences in index levels were found by histology (4.3, n = 25, adenocarcinoma vs 8.7. n = 18, squamous cell carcinoma vs 64.8, n = 2, large-cell carcinoma vs 9.8, n = 7, small-cell carcinoma; P= 0.0109). High anti-p53 antibody index levels were observed for both large-cell carcinoma and small-cell carcinoma. When the cut-off level was set at 7.2, determined using the twice 95% specificity level for normal volunteers, the sensitivities of anti-p53 antibodies were 46.1% for all lung cancers, 28.0% for adenocarcinoma, 55.6% for squamous cell carcinoma, 100% for large-cell carcinoma and 71.4% for small-cell carcinoma. However, there were no significant differences in index level by gender, age, smoking index, presence of previous or concomitant cancer or disease stage. Mulfivariate analysis using a logistic regression model demonstrated that histological type of tumour was a dominant factor associated with elevation of anti-p53 antibody index level (P= 0.0184). These findings suggest that serum anti-p53 antibody index level might be independent of tumour burden and the presence of previous or concomitant cancer in our series of lung cancer patients, but is clearly strongly correlated with tumour histological type.

show abstract

Circulating antibodies against p53 protein in patients with ovarian carcinoma

Angelopoulou

Rosen

Stratis

et al. 1996

Cancer

View full text Add to dashboard Cite

show abstract

Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer

Cited by 121 publications

References 6 publications

Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study

Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study

Measurement and evaluation of serum anti-p53 antibody levels in patients with lung cancer at its initial presentation: a prospective study

Circulating antibodies against p53 protein in patients with ovarian carcinoma

Contact Info

Product

Resources

About